$ZNTL
Zentalis Pharmaceuticals, Inc. Stock $zntl

$zntl Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000172516024000080 Filed on February 27, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$40.56M	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.74M	$16.36M	$64.35M
YoY Change	-3.84%	46.93%	17.96%
% of Gross Profit
Research & Development	$49.59M	$51.56M	$189.6M
YoY Change	2.06%	26.94%	9.76%
% of Gross Profit
Depreciation & Amortization	$324.0K	$337.0K	$1.400M
YoY Change	-10.0%	-6.13%	0.0%
% of Gross Profit
Operating Expenses	$65.33M	$67.92M	$299.5M
YoY Change	0.57%	31.24%	31.78%
Operating Profit	-$24.77M		-$299.5M
YoY Change	-61.87%		31.78%
Interest Expense	$34.95M	$6.848M	$22.62M
YoY Change	750.52%	111.88%	277.77%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	$10.18M	-$61.07M	-$292.9M
YoY Change	-116.74%	25.87%	23.29%
Income Tax	$143.0K	-$135.0K	-$601.0K
% Of Pretax Income	1.4%
Net Earnings	$10.07M	-$60.92M	-$292.2M
YoY Change	-115.93%	10.82%	23.39%
Net Earnings / Revenue	24.82%
Basic Earnings Per Share	$0.14		-$4.47
Diluted Earnings Per Share	$0.14	-$0.86	-$4.47
COMMON SHARES
Basic Shares Outstanding	70.96M shares	70.77M shares	65.41M shares
Diluted Shares Outstanding	71.19M shares		65.41M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$489.0M	$482.9M	$482.9M
YoY Change	24.58%	10.41%	10.41%
Cash & Equivalents	$37.62M	$28.04M	$28.04M
Short-Term Investments	$451.4M	$454.9M	$454.9M
Other Short-Term Assets	$11.67M	$10.46M	$10.46M
YoY Change	23.93%	-28.16%	27.9%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$503.8M	$496.7M	$496.7M
YoY Change	22.81%	9.91%	9.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.679M	$5.819M	$41.74M
YoY Change	-17.46%	-24.48%	-16.66%
Goodwill	$3.736M	$3.736M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$9.532M	$9.499M	$9.499M
YoY Change	-21.37%	-23.09%	-23.09%
Total Long-Term Assets	$53.67M	$54.97M	$54.97M
YoY Change	-32.16%	-37.09%	-37.09%
TOTAL ASSETS
Total Short-Term Assets	$503.8M	$496.7M	$496.7M
Total Long-Term Assets	$53.67M	$54.97M	$54.97M
Total Assets	$557.5M	$551.7M	$551.7M
YoY Change	13.92%	2.3%	2.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.50M	$14.93M	$14.93M
YoY Change	-18.07%	32.71%	32.71%
Accrued Expenses	$44.30M	$54.44M	$54.16M
YoY Change	1.74%	19.91%	20.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$54.80M	$69.37M	$69.37M
YoY Change	-2.77%	22.45%	22.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.294M	$1.780M	$44.93M
YoY Change	-27.79%	-32.06%	-5.98%
Total Long-Term Liabilities	$1.294M	$1.780M	$44.93M
YoY Change	-27.79%	-32.06%	-5.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$54.80M	$69.37M	$69.37M
Total Long-Term Liabilities	$1.294M	$1.780M	$44.93M
Total Liabilities	$98.71M	$114.3M	$114.4M
YoY Change	-4.79%	8.56%	8.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$878.5M	-$888.6M
YoY Change	33.19%	49.0%
Common Stock	$70.00K	$70.00K
YoY Change	18.64%	18.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$458.8M	$437.3M	$437.3M
YoY Change
Total Liabilities & Shareholders Equity	$557.5M	$551.7M	$551.7M
YoY Change	13.92%	2.3%	2.3%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$10.07M	-$60.92M	-$292.2M
YoY Change	-115.93%	10.82%	23.39%
Depreciation, Depletion And Amortization	$324.0K	$337.0K	$1.400M
YoY Change	-10.0%	-6.13%	0.0%
Cash From Operating Activities	-$51.97M	-$40.60M	-$207.8M
YoY Change	5.46%	8.76%	26.91%
INVESTING ACTIVITIES
Capital Expenditures	$40.00K	$173.0K	$583.0K
YoY Change		8.12%	-77.12%
Acquisitions
YoY Change
Other Investing Activities	$61.59M	-$41.89M	-$43.88M
YoY Change	46.21%	256.97%	-60.7%
Cash From Investing Activities	$61.55M	-$42.06M	-$44.46M
YoY Change	46.11%	253.62%	-61.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$235.7M
YoY Change			-8.62%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$7.000K	0.000	$237.3M
YoY Change	-98.12%	-100.0%	-9.09%
NET CHANGE
Cash From Operating Activities	-$51.97M	-40.60M	-$207.8M
Cash From Investing Activities	$61.55M	-42.06M	-$44.46M
Cash From Financing Activities	$7.000K	0.000	$237.3M
Net Change In Cash	$9.578M	-82.66M	-$14.98M
YoY Change	-241.08%	-16057.34%	-11.32%
FREE CASH FLOW
Cash From Operating Activities	-$51.97M	-$40.60M	-$207.8M
Capital Expenditures	$40.00K	$173.0K	$583.0K
Free Cash Flow	-$52.01M	-$40.77M	-$208.4M
YoY Change	5.54%	8.76%	25.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001725160
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39263
CY2023	dei	Entity Registrant Name EntityRegistrantName	Zentalis Pharmaceuticals, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3607803
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1359 Broadway
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 801
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10018
CY2023	dei	City Area Code CityAreaCode	212
CY2023	dei	Local Phone Number LocalPhoneNumber	433-3791
CY2023	dei	Security12b Title Security12bTitle	Common stock,$0.001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	ZNTL
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1560000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70960165	shares
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28038000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43069000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	454881000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	394302000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13799000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14562000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	496718000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	451933000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5819000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7705000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35916000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42373000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	6818000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	9723000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3736000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3736000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	21213000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2681000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2627000	usd
CY2023Q4	us-gaap	Assets Assets	551688000	usd
CY2022Q4	us-gaap	Assets Assets	539310000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14926000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11247000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	54441000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45400000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	69367000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	56647000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	853000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	43150000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45166000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1780000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2620000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	114297000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	105286000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70765554	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70765554	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59280247	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59280247	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	70000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	59000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1323576000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1031462000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2194000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1353000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-888556000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-596365000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	437284000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	433803000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	107000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	221000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	437391000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	434024000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	551688000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	539310000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	189590000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	172734000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	175601000	usd
CY2023	zntl	Asset Acquisition Research And Development Expense AssetAcquisitionResearchAndDevelopmentExpense	45568000	usd
CY2022	zntl	Asset Acquisition Research And Development Expense AssetAcquisitionResearchAndDevelopmentExpense	0	usd
CY2021	zntl	Asset Acquisition Research And Development Expense AssetAcquisitionResearchAndDevelopmentExpense	0	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	64351000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	54553000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40941000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	299509000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	227287000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	216542000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-299509000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-227287000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-216542000	usd
CY2023	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	22617000	usd
CY2022	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	5987000	usd
CY2021	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	401000	usd
CY2023	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	usd
CY2022	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	usd
CY2021	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	51582000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-276892000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-221300000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-164559000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-601000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-469000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-297000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-16014000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-16282000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1831000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-292305000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-237113000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-166093000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-114000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-307000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7368000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-292191000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-236806000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-158725000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.47
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.47
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.48
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.48
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.72
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.72
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65409000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65409000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52857000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52857000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42688000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42688000	shares
CY2023	us-gaap	Profit Loss ProfitLoss	-292305000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-237113000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-166093000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3547000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1228000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-161000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-288758000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-238341000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-166254000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-114000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-307000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-7368000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-288644000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-238034000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-158886000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	333377000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35737000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	171973000	usd
CY2021	zntl	Adjustments To Additional Paid In Capital Issuance And Withholding Of Common Stock In Connection With Restricted Stock Unit Vesting Net AdjustmentsToAdditionalPaidInCapitalIssuanceAndWithholdingOfCommonStockInConnectionWithRestrictedStockUnitVestingNet	1146000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7149000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	545000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-161000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7368000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-158725000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	364482000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	364482000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	46840000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	257922000	usd
CY2022	zntl	Adjustments To Additional Paid In Capital Issuance And Withholding Of Common Stock In Connection With Restricted Stock Unit Vesting Net AdjustmentsToAdditionalPaidInCapitalIssuanceAndWithholdingOfCommonStockInConnectionWithRestrictedStockUnitVestingNet	-1000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2246000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	874000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1228000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-307000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-236806000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	434024000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	434024000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	54822000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3547000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	235680000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	995000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	628000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-114000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-292191000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	437391000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-292305000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-237113000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-166093000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1389000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1426000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	544000	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	4953000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	8800000	usd
CY2023	zntl	Recognized Tax Gain On Intangible Asset Impairment RecognizedTaxGainOnIntangibleAssetImpairment	0	usd
CY2022	zntl	Recognized Tax Gain On Intangible Asset Impairment RecognizedTaxGainOnIntangibleAssetImpairment	0	usd
CY2021	zntl	Recognized Tax Gain On Intangible Asset Impairment RecognizedTaxGainOnIntangibleAssetImpairment	2462000	usd
CY2023	zntl	Deconsolidation Gain Loss Amount Net DeconsolidationGainLossAmountNet	0	usd
CY2022	zntl	Deconsolidation Gain Loss Amount Net DeconsolidationGainLossAmountNet	0	usd
CY2021	zntl	Deconsolidation Gain Loss Amount Net DeconsolidationGainLossAmountNet	49930000	usd
CY2023	zntl	Noncash To Acquire In Process Research And Development NoncashToAcquireInProcessResearchAndDevelopment	15045000	usd
CY2022	zntl	Noncash To Acquire In Process Research And Development NoncashToAcquireInProcessResearchAndDevelopment	0	usd
CY2021	zntl	Noncash To Acquire In Process Research And Development NoncashToAcquireInProcessResearchAndDevelopment	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	54822000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	46840000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	35737000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-406000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-56000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-15000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	13157000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	3725000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-908000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-16014000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-16282000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1831000	usd
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-853000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-769000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-48000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5678000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6605000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1294000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10919000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	15527000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13964000	usd
CY2023	zntl	Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet	623000	usd
CY2022	zntl	Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet	4330000	usd
CY2021	zntl	Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet	1347000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-207822000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-163751000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-154093000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	549182000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	533161000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	363508000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	505307000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	421529000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	365820000	usd
CY2023	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	0	usd
CY2022	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	0	usd
CY2021	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	14320000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	583000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2548000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6107000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-44458000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-114180000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18115000	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1623000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3121000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7694000	usd
CY2023	zntl	Share Based Payment Arrangement Net Settlement Of Restricted Stock Unit Vesting ShareBasedPaymentArrangementNetSettlementOfRestrictedStockUnitVesting	0	usd
CY2022	zntl	Share Based Payment Arrangement Net Settlement Of Restricted Stock Unit Vesting ShareBasedPaymentArrangementNetSettlementOfRestrictedStockUnitVesting	0	usd
CY2021	zntl	Share Based Payment Arrangement Net Settlement Of Restricted Stock Unit Vesting ShareBasedPaymentArrangementNetSettlementOfRestrictedStockUnitVesting	1146000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	235680000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	257922000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	171973000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	237303000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	261043000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	178521000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14977000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16888000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6313000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45696000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62584000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	56271000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30719000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45696000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62584000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	140000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	12000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	20000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	602000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	44613000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1510000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28038000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43069000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59714000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	243000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2681000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2627000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2627000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30719000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45696000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62584000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></div>
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	2700000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	2600000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Sources of Supply</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolios of cash equivalents and marketable securities. We maintain our cash and cash equivalent and marketable securities balances with major commercial banks. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets. We have also established guidelines to limit our exposure to credit risk by diversifying our marketable securities portfolio and placing them in investments with maturities that maintain safety and liquidity. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party manufacturers for the supply of active pharmaceutical ingredients.</span></div>
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	54324	shares
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	27.91
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y7M6D
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	15.48
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	20.45
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	33.27
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2000000	usd
CY2023Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-13700000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	452686000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2299000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	104000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	454881000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	395655000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	71000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1424000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	394302000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	20	security
CY2023Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	113400000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	100000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	267336000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	394302000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	187545000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	454881000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	394302000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	4755000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	454881000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	459636000	usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	500000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	500000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	28809000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	394302000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	423111000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	0	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	747000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1018000	usd
CY2023Q4	zntl	Prepaid Software License And Maintenance PrepaidSoftwareLicenseAndMaintenance	691000	usd
CY2022Q4	zntl	Prepaid Software License And Maintenance PrepaidSoftwareLicenseAndMaintenance	958000	usd
CY2023Q4	zntl	Foreign Research And Development Credit Refund ForeignResearchAndDevelopmentCreditRefund	500000	usd
CY2022Q4	zntl	Foreign Research And Development Credit Refund ForeignResearchAndDevelopmentCreditRefund	659000	usd
CY2023Q4	zntl	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	13640000	usd
CY2022Q4	zntl	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	15002000	usd
CY2023Q4	us-gaap	Interest Receivable InterestReceivable	3337000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	508000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	1471000	usd
CY2022Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	0	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	5874000	usd
CY2023Q4	zntl	Other Prepaid Expense OtherPrepaidExpense	231000	usd
CY2022Q4	zntl	Other Prepaid Expense OtherPrepaidExpense	266000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	20617000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	24285000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	6818000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	9723000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13799000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14562000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2620000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	54441000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45400000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8967000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9765000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3148000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2060000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5819000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7705000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1400000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1400000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	usd
CY2023Q4	zntl	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	36261000	usd
CY2022Q4	zntl	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	32310000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14477000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11246000	usd
CY2023Q4	zntl	Accrued General And Administrative Costs Current AccruedGeneralAndAdministrativeCostsCurrent	1032000	usd
CY2022Q4	zntl	Accrued General And Administrative Costs Current AccruedGeneralAndAdministrativeCostsCurrent	662000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2623000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2162000	usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	500000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	281000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	384000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1047000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1256000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	56221000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	48020000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1780000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8800000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	54822000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	46840000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35737000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	54822000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	46840000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35737000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8051459	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.97
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3772345	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	22.17
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	54324	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	18.31
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1752045	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	32.82
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10017435	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.59
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	160000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10017435	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	26.59
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y9M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	160000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4086661	shares
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	5000000.0	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	900000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	6900000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	7000000.0	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	2700000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	6400000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2500000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1300000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y8M12D
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6643000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7002000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7487000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7606000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	7760000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	31018000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	67516000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	21743000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	45773000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2623000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	43150000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-293284000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-237926000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-171053000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	378000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	344000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	4663000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-292906000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-237582000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-166390000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	41000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	249000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	298000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	550000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	290000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	309000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	561000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-891000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-683000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-120000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-41000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-736000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-54000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-2000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-891000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-778000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-858000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-601000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-469000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-297000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-61509000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-49892000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-34941000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2384000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.008
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4222000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.018
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-931000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.006
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	2031000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.007
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	12558000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.053
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	6938000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.042
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	3008000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.010
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	1245000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-3307000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.020
CY2023	zntl	Effective Income Tax Rate Reconciliation Deemed Royalty Amount EffectiveIncomeTaxRateReconciliationDeemedRoyaltyAmount	8263000	usd
CY2023	zntl	Effective Income Tax Rate Reconciliation Deemed Royalty Percent EffectiveIncomeTaxRateReconciliationDeemedRoyaltyPercent	-0.028
CY2022	zntl	Effective Income Tax Rate Reconciliation Deemed Royalty Amount EffectiveIncomeTaxRateReconciliationDeemedRoyaltyAmount	0	usd
CY2022	zntl	Effective Income Tax Rate Reconciliation Deemed Royalty Percent EffectiveIncomeTaxRateReconciliationDeemedRoyaltyPercent	0
CY2021	zntl	Effective Income Tax Rate Reconciliation Deemed Royalty Amount EffectiveIncomeTaxRateReconciliationDeemedRoyaltyAmount	0	usd
CY2021	zntl	Effective Income Tax Rate Reconciliation Deemed Royalty Percent EffectiveIncomeTaxRateReconciliationDeemedRoyaltyPercent	0
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	586000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-2799000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.012
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	939000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2023	zntl	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162m Limitations Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162mLimitationsAmount	5028000	usd
CY2023	zntl	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162m Limitations Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162mLimitationsPercent	-0.017
CY2022	zntl	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162m Limitations Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162mLimitationsAmount	3950000	usd
CY2022	zntl	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162m Limitations Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162mLimitationsPercent	-0.017
CY2021	zntl	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162m Limitations Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162mLimitationsAmount	3982000	usd
CY2021	zntl	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162m Limitations Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162mLimitationsPercent	-0.024
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-10420000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.036
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	58858000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.201
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	63807000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.269
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	40899000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.246
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-601000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.002
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-469000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.002
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-297000	usd
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.002
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	96676000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	95392000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	2451000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1937000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11486000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7735000	usd
CY2023Q4	zntl	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	11131000	usd
CY2022Q4	zntl	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	9967000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	11185000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1745000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	66500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	30776000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1163000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	476000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	29055000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	27024000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	22000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	62000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	229669000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	175114000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	219292000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	160967000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10377000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	14147000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1108000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1609000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	8734000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	8924000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	4467000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	497000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	10339000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	15000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	38000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	853000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	219300000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	161000000.0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4297000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2835000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1932000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	857000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1112000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	969000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	350000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	940000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	66000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4214000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4297000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2835000	usd
CY2023Q4	zntl	Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate	3900000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-292191000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-236806000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-158725000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65409000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65409000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52857000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52857000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42688000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42688000	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.47
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.47
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.48
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.48
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.72
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.72
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11237000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9100000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4538000	shares
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1500000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1400000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1000000.0	usd

Files In Submission

Name	View Source	Status
0001725160-24-000080-index-headers.html	Edgar Link	pending
0001725160-24-000080-index.html	Edgar Link	pending
0001725160-24-000080.txt	Edgar Link	pending
0001725160-24-000080-xbrl.zip	Edgar Link	pending
consent.htm	Edgar Link	pending
ex1015-brownsteincxzenta.htm	Edgar Link	pending
ex1015-brownsteincxzenta001.jpg	Edgar Link	pending
ex1015-brownsteincxzenta002.jpg	Edgar Link	pending
ex1015-brownsteincxzenta003.jpg	Edgar Link	pending
ex1015-brownsteincxzenta004.jpg	Edgar Link	pending
ex1015-brownsteincxzenta005.jpg	Edgar Link	pending
ex1015-brownsteincxzenta006.jpg	Edgar Link	pending
ex1015-brownsteincxzenta007.jpg	Edgar Link	pending
ex1015-brownsteincxzenta008.jpg	Edgar Link	pending
ex1015-brownsteincxzenta009.jpg	Edgar Link	pending
ex1015-brownsteincxzenta010.jpg	Edgar Link	pending
ex1015-brownsteincxzenta011.jpg	Edgar Link	pending
ex1015-brownsteincxzenta012.jpg	Edgar Link	pending
ex1015-brownsteincxzenta013.jpg	Edgar Link	pending
ex1015-brownsteincxzenta014.jpg	Edgar Link	pending
ex1015-brownsteincxzenta015.jpg	Edgar Link	pending
ex1015-brownsteincxzenta016.jpg	Edgar Link	pending
ex1016-brownsteincxzenta.htm	Edgar Link	pending
ex1016-brownsteincxzenta001.jpg	Edgar Link	pending
ex1016-brownsteincxzenta002.jpg	Edgar Link	pending
ex1016-brownsteincxzenta003.jpg	Edgar Link	pending
ex1016-brownsteincxzenta004.jpg	Edgar Link	pending
ex1016-brownsteincxzenta005.jpg	Edgar Link	pending
ex1016-brownsteincxzenta006.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx.htm	Edgar Link	pending
ex1018-bunkerkxzentalisx001.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx002.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx003.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx004.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx005.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx006.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx007.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx008.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx009.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx010.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx011.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx012.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx013.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx014.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx015.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx016.jpg	Edgar Link	pending
ex1018-bunkerkxzentalisx017.jpg	Edgar Link	pending
ex1019-bunkerkxzentalisx.htm	Edgar Link	pending
ex1019-bunkerkxzentalisx001.jpg	Edgar Link	pending
ex1019-bunkerkxzentalisx002.jpg	Edgar Link	pending
ex1019-bunkerkxzentalisx003.jpg	Edgar Link	pending
ex1019-bunkerkxzentalisx004.jpg	Edgar Link	pending
ex1019-bunkerkxzentalisx005.jpg	Edgar Link	pending
ex1019-bunkerkxzentalisx006.jpg	Edgar Link	pending
ex1020-bunkerkxzentalisx.htm	Edgar Link	pending
ex1020-bunkerkxzentalisx001.jpg	Edgar Link	pending
ex1020-bunkerkxzentalisx002.jpg	Edgar Link	pending
ex1020-bunkerkxzentalisx003.jpg	Edgar Link	pending
ex1020-bunkerkxzentalisx004.jpg	Edgar Link	pending
ex1020-bunkerkxzentalisx005.jpg	Edgar Link	pending
ex1023-lacknermxzentalis.htm	Edgar Link	pending
ex1023-lacknermxzentalis001.jpg	Edgar Link	pending
ex1023-lacknermxzentalis002.jpg	Edgar Link	pending
ex1023-lacknermxzentalis003.jpg	Edgar Link	pending
ex1023-lacknermxzentalis004.jpg	Edgar Link	pending
ex1023-lacknermxzentalis005.jpg	Edgar Link	pending
ex1023-lacknermxzentalis006.jpg	Edgar Link	pending
ex1023-lacknermxzentalis007.jpg	Edgar Link	pending
ex1023-lacknermxzentalis008.jpg	Edgar Link	pending
ex1023-lacknermxzentalis009.jpg	Edgar Link	pending
ex1023-lacknermxzentalis010.jpg	Edgar Link	pending
ex1023-lacknermxzentalis011.jpg	Edgar Link	pending
ex1023-lacknermxzentalis012.jpg	Edgar Link	pending
ex1023-lacknermxzentalis013.jpg	Edgar Link	pending
ex1023-lacknermxzentalis014.jpg	Edgar Link	pending
ex1023-lacknermxzentalis015.jpg	Edgar Link	pending
ex1023-lacknermxzentalis016.jpg	Edgar Link	pending
ex1023-lacknermxzentalis017.jpg	Edgar Link	pending
ex1023-lacknermxzentalis018.jpg	Edgar Link	pending
ex1023-lacknermxzentalis019.jpg	Edgar Link	pending
ex1023-lacknermxzentalis020.jpg	Edgar Link	pending
ex1024-hausmandxzentalis.htm	Edgar Link	pending
ex1024-hausmandxzentalis001.jpg	Edgar Link	pending
ex1024-hausmandxzentalis002.jpg	Edgar Link	pending
ex1024-hausmandxzentalis003.jpg	Edgar Link	pending
ex1024-hausmandxzentalis004.jpg	Edgar Link	pending
ex1024-hausmandxzentalis005.jpg	Edgar Link	pending
ex1024-hausmandxzentalis006.jpg	Edgar Link	pending
ex1024-hausmandxzentalis007.jpg	Edgar Link	pending
ex1024-hausmandxzentalis008.jpg	Edgar Link	pending
ex1024-hausmandxzentalis009.jpg	Edgar Link	pending
ex1024-hausmandxzentalis010.jpg	Edgar Link	pending
ex1024-hausmandxzentalis011.jpg	Edgar Link	pending
ex1024-hausmandxzentalis012.jpg	Edgar Link	pending
ex1024-hausmandxzentalis013.jpg	Edgar Link	pending
ex1024-hausmandxzentalis014.jpg	Edgar Link	pending
ex1024-hausmandxzentalis015.jpg	Edgar Link	pending
ex1024-hausmandxzentalis016.jpg	Edgar Link	pending
ex1024-hausmandxzentalis017.jpg	Edgar Link	pending
ex1024-hausmandxzentalis018.jpg	Edgar Link	pending
ex1024-hausmandxzentalis019.jpg	Edgar Link	pending
ex1061-zentalisx2022empl.htm	Edgar Link	pending
ex1061-zentalisx2022empl001.jpg	Edgar Link	pending
ex1061-zentalisx2022empl002.jpg	Edgar Link	pending
ex1061-zentalisx2022empl003.jpg	Edgar Link	pending
ex1061-zentalisx2022empl004.jpg	Edgar Link	pending
ex1061-zentalisx2022empl005.jpg	Edgar Link	pending
ex1061-zentalisx2022empl006.jpg	Edgar Link	pending
ex1061-zentalisx2022empl007.jpg	Edgar Link	pending
ex1061-zentalisx2022empl008.jpg	Edgar Link	pending
ex1061-zentalisx2022empl009.jpg	Edgar Link	pending
ex1061-zentalisx2022empl010.jpg	Edgar Link	pending
ex1061-zentalisx2022empl011.jpg	Edgar Link	pending
ex1061-zentalisx2022empl012.jpg	Edgar Link	pending
ex1061-zentalisx2022empl013.jpg	Edgar Link	pending
ex1061-zentalisx2022empl014.jpg	Edgar Link	pending
ex1061-zentalisx2022empl015.jpg	Edgar Link	pending
ex1061-zentalisx2022empl016.jpg	Edgar Link	pending
ex1061-zentalisx2022empl017.jpg	Edgar Link	pending
ex1092-zentalispharmaceu.htm	Edgar Link	pending
ex1092-zentalispharmaceu001.jpg	Edgar Link	pending
ex1092-zentalispharmaceu002.jpg	Edgar Link	pending
ex1092-zentalispharmaceu003.jpg	Edgar Link	pending
ex1092-zentalispharmaceu004.jpg	Edgar Link	pending
ex1092-zentalispharmaceu005.jpg	Edgar Link	pending
ex1092-zentalispharmaceu006.jpg	Edgar Link	pending
ex1092-zentalispharmaceu007.jpg	Edgar Link	pending
ex1092-zentalispharmaceu008.jpg	Edgar Link	pending
ex1092-zentalispharmaceu009.jpg	Edgar Link	pending
ex1092-zentalispharmaceu010.jpg	Edgar Link	pending
ex1092-zentalispharmaceu011.jpg	Edgar Link	pending
ex1092-zentalispharmaceu012.jpg	Edgar Link	pending
ex1092-zentalispharmaceu013.jpg	Edgar Link	pending
ex1092-zentalispharmaceu014.jpg	Edgar Link	pending
ex1092-zentalispharmaceu015.jpg	Edgar Link	pending
ex1092-zentalispharmaceu016.jpg	Edgar Link	pending
ex1092-zentalispharmaceu017.jpg	Edgar Link	pending
ex97-zentalisxclawbackpoli.htm	Edgar Link	pending
exhibit103-nonxemployeedir.htm	Edgar Link	pending
exhibit211-listofsubsidiar.htm	Edgar Link	pending
exhibit311-zentalis10xk2023.htm	Edgar Link	pending
exhibit312-zentalis10xk2023.htm	Edgar Link	pending
exhibit321-zentalis10xk2023.htm	Edgar Link	pending
exhibit322-zentalis10xk2023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zntl-20231231.htm	Edgar Link	pending
zntl-20231231.xsd	Edgar Link	pending
zntl-20231231_g1.jpg	Edgar Link	pending
zntl-20231231_g2.jpg	Edgar Link	pending
zntl-20231231_cal.xml	Edgar Link	unprocessable
zntl-20231231_def.xml	Edgar Link	unprocessable
zntl-20231231_lab.xml	Edgar Link	unprocessable
zntl-20231231_pre.xml	Edgar Link	unprocessable
zntl-20231231_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZNTL
Zentalis Pharmaceuticals, Inc. Stock $zntl

2024 Q1 Form 10-K Financial Statement

#000172516024000080 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZNTL Zentalis Pharmaceuticals, Inc. Stock $zntl

2024 Q1 Form 10-K Financial Statement

#000172516024000080 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZNTL
Zentalis Pharmaceuticals, Inc. Stock $zntl